SCHEMBL99549

SCHEMBL99549

CCC([C]=O)S(N)(=O)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10523738 0.76
SCHEMBL20876138 0.74
SCHEMBL2949167 0.73
SCHEMBL28367673 0.69 CA2 (0.41)
SCHEMBL7290545 0.69 CA1 (0.37)
SCHEMBL9343213 0.67
SCHEMBL11141576 0.65 CA2 (0.36)
SCHEMBL224724 0.65
SCHEMBL27956515 0.65
SCHEMBL6200806 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008133344-A2 PIPERIDINE DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 WO claimed
US-20080275085-A1 Piperidine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-11-06 US claimed
US-20050272646-A1 Streptogramin antibiotics MCMASTER UNIVERSITY 2005-12-08 US claimed
EP-4262879-A1 OLIGOMERIC COMPOUNDS BINDING SPECIFICALLY TO PROTEOGLYCANS Phi Pharma SA (CH) 2023-10-25 EP disclosed
WO-2022129627-A1 OLIGOMERIC COMPOUNDS BINDING SPECIFICALLY TO PROTEOGLYCANS PHI PHARMA SA (CH) 2022-06-23 WO disclosed
EP-2426139-B1 CXCR4 antagonist and use thereof BIOKINE THERAPEUTICS LTD (IL) 2014-10-01 EP disclosed
WO-2013162760-A1 NOVEL CYCLOTIDES WITH ANTICANCER ACTIVITY UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2013-10-31 WO disclosed
CN-101801995-B Antibacterial peptide AMP THERAPEUTICS GMBH & CO KG 2013-10-30 CN disclosed
US-8410059-B2 CXCR4 antagonist and use thereof BIOKINE THERAPEUTICS LTD. (IL) 2013-04-02 US disclosed
EP-1541585-B1 CXCR4 ANTAGONIST AND USE THEREOF BIOKINE THERAPEUTICS LTD (IL) 2013-01-30 EP disclosed
EP-1732609-B1 CONJUGATES OF HYDROXYALKYL STARCH AND A PROTEIN FRESENIUS KABI DE GMBH (DE) 2012-07-11 EP disclosed
US-7169756-B2 Streptogramin antibiotics MCMASTER UNIVERSITY (CA) 2007-01-30 US disclosed
EP-1732609-A2 CONJUGATES OF HYDROXYALKYL STARCH AND A PROTEIN Fresenius Kabi Deutschland GmbH (DE) 2006-12-20 EP disclosed
US-20060264378-A1 Cxcr4 antagonist and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-11-23 US disclosed
US-20060134691-A1 Labeling methodology comprising oligopeptides AUER MANFRED 2006-06-22 US disclosed
US-20050272646-A1 Streptogramin antibiotics MCMASTER UNIVERSITY 2005-12-08 US disclosed
WO-2005092391-A2 CONJUGATES OF HYDROXYALKYL STARCH AND A PROTEIN FRESENIUS KABI DEUTSCHLAND GMBH (DE) 2005-10-06 WO disclosed
EP-1541585-A1 CXCR4 ANTAGONIST AND USE THEREOF Fujii, Nobutaka (JP) 2005-06-15 EP disclosed
WO-2004051270-A2 LABELING METHODOLOGY COMPRISING OLIGOPEPTIDES NOVARTIS AG (CH) 2004-06-17 WO disclosed
WO-1999040435-A1 PROTEIN FOLDING INHIBITORS NETZER WILLIAM J (US) 1999-08-12 WO disclosed